Real-World Rearranged during Transfection [RET]-Alteration Testing, Treatment and Referral Patterns of Patients with Medullary and Papillary Thyroid Cancer [MTC, PTC] in Taiwan
Author(s)
Segall G1, Chang A2, Wei A2, Kiiskinen U3, Jen MH4, Sanderson I5, Lewis K5, Rider A5
1Eli Lilly and Company, Gerrards Cross, UK, 2Eli Lilly and Company (Taiwan), Taipei, Taiwan, 3Eli Lilly and Company, Helsinki, Finland, 4Eli Lilly and Company, Uxbridge, LON, UK, 5Adelphi Real World, Bollington, UK
Presentation Documents
OBJECTIVES:
RET-fusions occur in ~10-20% of PTC patients, and RET-mutations in ~60% of MTC patients. RET-alteration testing can identify patients who could benefit from RET-targeted treatments, available through early-access in Taiwan at the time of this study. Consequently, this study describes RET-alteration testing, treatment and referral patterns for MTC and PTC patients in Taiwan.METHODS:
Data were drawn from the Adelphi Thyroid Cancer Disease Specific Programme™, a point-in-time survey of clinicians and their patients. Between July-September 2021, physicians in Taiwan abstracted medical records for their next 4 presenting advanced thyroid cancer patients, providing referral, testing and treatment pattern information.RESULTS:
Data were collected from 30 Taiwanese physicians, mostly haematologists/ medical oncologists (60%) and mostly practicing in private hospitals (57%). Physicians recruited 24 MTC and 133 PTC patients. Patients' median age was 55 (IQR:45-64.8) and 58 (IQR:49.5-68.5) years for MTC and PTC respectively. Overall, 46% and 9% of MTC and PTC patients respectively were tested for RET-alteration, by single-gene testing or as part of multi-gene Next Generation Sequencing (NGS). Half of MTC patients were tested by Polymerase Chain Reaction, half by NGS. Most PTC patients underwent NGS testing (58%). 40% of MTC patients were RET-mutation-positive, whereas no PTC patients were RET-fusion-positive. 50% of MTC and 61% of PTC patients underwent surgery for advanced disease. 42% of MTC patients and 43% of PTC patients received first-line (1L) drug treatment. Of those, 50% of MTC patients received Sorafenib and 61% of PTC patients received Lenvatinib. Endocrinologists were the predominant specialty involved at advanced stage diagnosis (58%/73% of MTC/PTC patients), whilst haematologists/ medical oncologists primarily were involved at 1L drug treatment (62%/59% of MTC/PTC patients).CONCLUSIONS:
Despite early access to RET-targeted treatments in Taiwan, RET-alteration testing was infrequent and could be improved to identify patients who could benefit from such treatments in future.Conference/Value in Health Info
2023-05, ISPOR 2023, Boston, MA, USA
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
HSD30
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), Drugs, Personalized & Precision Medicine, Rare & Orphan Diseases